Clinical cancer research, 2018-04, Vol.24 (8), p.1795-1804
2018
Details
- Autor(en) / Beteiligte
- Titel
- Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
- Ist Teil von
- Clinical cancer research, 2018-04, Vol.24 (8), p.1795-1804
- Ort / Verlag
- United States: American Association for Cancer Research Inc
- Erscheinungsjahr
- 2018
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- The brain is the most common site of first metastasis for patients with HER2-positive breast cancer treated with HER2-targeting drugs. However, the development of effective therapies for breast cancer brain metastases (BCBM) is limited by an incomplete understanding of the mechanisms governing drug sensitivity in the central nervous system. Pharmacodynamic data from patients and models suggest that inadequate drug penetration across the "blood-tumor" barrier is not the whole story. Using HER2-positive BCBMs as a case study, we highlight recent data from orthotopic brain metastasis models that implicate brain-specific drug resistance mechanisms in BCBMs and suggest a translational research paradigm to guide drug development for treatment of BCBMs. .
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1078-0432eISSN: 1557-3265DOI: 10.1158/1078-0432.CCR-17-3351Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5899637
- Format
- –
- Schlagworte
- Adaptation, Physiological, Animals, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Blood-Brain Barrier - drug effects, Blood-Brain Barrier - metabolism, Brain, Brain Neoplasms - diagnosis, Brain Neoplasms - drug therapy, Brain Neoplasms - secondary, Breast cancer, Breast Neoplasms - genetics, Breast Neoplasms - metabolism, Breast Neoplasms - pathology, Cancer, Case studies, Central nervous system, Clinical Studies as Topic, Disease Models, Animal, Drug delivery, Drug Development, Drug Evaluation, Preclinical, Drug resistance, Drug Resistance, Neoplasm - genetics, ErbB-2 protein, Female, Humans, Metastases, Metastasis, Mice, Models, Biological, Patients, Pharmacodynamics, Pharmacology, Receptor, ErbB-2 - genetics, Receptor, ErbB-2 - metabolism, Translational Medical Research, Treatment Outcome, Xenograft Model Antitumor Assays